
Intern Spotlight: Valeria Arango, Benicio Beatty, Ameya Komaragiri, Carlos Ponce de Leon Mendez, and Ella Salim
During the peak hour of a July summer day, CHERISH colleagues and interns from Boston Medical Center logged onto Zoom while investigators and staff in New York City filled a conference room located on the Upper East Side at Weill Cornell Medicine. Three minutes past twelve, Caroline Savitsky, program manager in the Section of Infectious […]

Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021
The economic burden of substance use disorder (SUD) is significant. It encompasses clinical and societal costs such as health care and social services, criminal justice resources, loss of productivity, and premature mortality, and is estimated to cost more than $700 billion per year in the United States. To understand the gravity of these economic costs, […]

Engaging with People with Lived Experiences in OUD Modeling Research
Drug overdose deaths continue to rise in the United States and Canada, with the risks for greater opioid use sharply increasing in Mexico. As modelers, we know simulation modeling is a valuable tool that can inform policies and interventions to prevent overdose deaths and reduce related harms including drug overdose, HIV, and hepatitis C virus […]

Lowering the Barriers to Medication Treatment for People with Opioid Use Disorder
Overdose deaths have reached unprecedented levels in the U.S., despite effective medications to treat opioid use disorders (OUDs). Because the regulatory and administrative barriers to treatment are high, only about 11% of people with OUD receive effective medications, which include buprenorphine, methadone, and naltrexone. In response, clinicians and advocates have looked to a “low-threshold” approach […]

Weighing the Costs and Benefits of Initiating Extended-release Injectable Naltrexone Compared to Buprenorphine-naloxone
Naltrexone and buprenorphine are two effective medications for opioid use disorder (OUD). Naltrexone, which is typically given as a monthly extended-release injection (XR-NTX), and daily oral buprenorphine, which is typically combined with naloxone (BUP-NX), are prescribed in outpatient or office-based medical settings. XR-NTX patients, however, need to complete detoxification before starting treatment. Results from a […]

Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use
Prescription drug monitoring programs (PDMPs) are statewide databases that track controlled substances dispensed at retail pharmacies. Used by health care providers, public health officials, and other stakeholders, PDMPs have become a major tool in addressing unsafe opioid prescriptions. Robust features of PDMPs—including mandates that allow prescriber use of PDMP, data-sharing across states, and prescriber delegation of […]

Hepatitis C Treatment by Non-specialist Providers in the Direct-acting Antiviral Era
Direct-acting antiviral agents (DAAs), highly effective treatments for hepatitis C virus infection (HCV), transformed HCV therapy and made it easier for non-specialist providers to prescribe HCV treatment. Despite this simplification, many insurers include being a specialist as part of prior authorization requirements for DAA treatment. CHERISH Research Affiliate and former pilot grant recipient Shashi N. […]

Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
In this systematic review, researchers affiliated with the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) including CHERISH staff Erica Onuoha and Jared Leff; CHERISH investigators Bruce R. Schackman, Kathryn E. McCollister, and Sean M. Murphy; and CHERISH Advisory Board member Daniel Polsky, identified new studies supporting buprenorphine and methadone as economically advantageous medications for […]

Harmonizing Healthcare and Other Resource Measures for Evaluating Economic Costs in Substance Use Disorder Research
Lindsay Allen, PhD, MA, Feinberg School of Medicine at Northwestern University The National Institute on Drug Abuse, or NIDA, considers data harmonization in substance use disorder, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) research a high-priority. Data harmonization allows investigators to synthesize data across independent studies and promote more rigorous and comparable analyses of […]

Dissemination Science to Advance the Use of Simulation Modeling
COVID-19 has brought simulation modeling to the foreground of public discourse, as policy makers and stakeholders project the effects of different interventions to “flatten the curve.” Simulation models allow investigators to tinker with different conditions of the world to observe how they affect future outcomes; however, translating the models’ results to the public can be […]

CHERISH Awarded Five-year Center of Excellence Grant to Continue Substance Use Health Economics Research
The National Institute on Drug Abuse (NIDA) of the National Institutes of Health has awarded the Center for Health Economics of Treatment Interventions for Substance Use, HCV and HIV (CHERISH) a five-year grant to continue the Center’s activities as a national center of excellence. CHERISH was founded in 2015 as a multi-institutional center for health […]

COVID-19 Can Change The Way We Respond To The Opioid Crisis – For The Better
The Coronavirus (COVID-19) pandemic has brought unprecedented challenges in healthcare delivery to people who use drugs. However, it may also have provided impetus to precipitate innovative changes in providing opioid overdose prevention, syringe services, and medication for opioid use disorder (MOUD) to this vulnerable population. In a new Viewpoint in Psychiatric Services, CHERISH Research Affiliate Yuhua Bao from […]
Engage with CHERISH
Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.